Related Experiment Video
Updated: Jan 1, 2026
Induction and Clinical Scoring of Chronic-Relapsing Experimental Autoimmune Encephalomyelitis
Published on: July 4, 2007
Neurodevelopmental outcomes in paediatric immune-mediated and autoimmune epileptic encephalopathy
Sukhvir K Wright1, Amanda G Wood2
1School of Life and Health Sciences & Aston Neuroscience Institute, Aston University, Birmingham, UK; Department of Neurology, Birmingham Children's Hospital, Birmingham, UK.
Insights
Paediatric autoimmune encephalitis and epileptic encephalopathy can lead to long-term cognitive and behavioral issues, even after medical recovery. Early surveillance is crucial for identifying children needing ongoing support.
Area of Science:
- Neuroscience
- Immunology
- Paediatrics
Background:
- Autoimmune/immune-mediated encephalitis and epileptic encephalopathy are increasingly recognized in children.
- While medical recovery rates are high, significant neurodevelopmental sequelae can persist.
- Standard outcome measures like MRS and PCPC do not capture these complex long-term difficulties.
Purpose of the Study:
- To review the literature on neurodevelopmental outcomes in paediatric autoimmune encephalitis.
- To provide guidance on post-onset surveillance for identifying at-risk children.
- To highlight the limitations of current medical outcome assessments.
Main Methods:
- Literature review of studies on neurodevelopmental outcomes.
- Analysis of current medical outcome assessment tools.
- Synthesis of findings to propose surveillance strategies.
Main Results:
- Children with autoimmune encephalitis experience a range of cognitive, social, and behavioral challenges.
- Existing medical outcome scales are insufficient for assessing these long-term impacts.
- Specific risk factors for poor neurodevelopmental outcomes require further investigation.
Conclusions:
- A "good" medical recovery does not equate to a full return to baseline functioning for paediatric patients.
- Comprehensive neurodevelopmental assessment and targeted surveillance are essential.
- Improved outcome measures and follow-up protocols are needed to address the long-term needs of affected children.
Abstract:
Recognition of paediatric autoimmune/immune-mediated encephalitis and epileptic encephalopathy (e.g. NMDAR-Ab encephalitis) has rapidly increased over the last ten years. While we are succeeding in the diagnosis and identification and even early treatment of these encephalitidies, with studies describing >80% are making a "good" recovery, we are now recognising that a "good" medical outcome does not cover the cognitive, social and behavioural sequelae that can occur, particularly in paediatric patients. Basic measures of medical outcome, for example the modified Rankin Scale (MRS) or the Paediatric Cerebral Performance Category (PCPC), offer the advantage of being quick to use, but do not reveal the more complex difficulties that can impact the future of affected children. This article reviews the current literature on neurodevelopmental outcomes in children affected with autoimmune and immune-mediated encephalitis/epileptic encephalopathy and provides guidance on post-onset surveillance aimed at identifying those most likely to experience ongoing long-term difficulties.
More Related Videos
Related Concept Videos
01:24Epilepsy and Seizures: Overview
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
01:14Antiepileptic Drugs: Glutamate Antagonists
01:18Antiepileptic Drugs: GABAergic Pathway Potentiators
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
01:20Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...